The North America facial injectables market is quite monopolistic in nature with one player dominating the overall market dynamics. As of 2016, Allergan Plc., held a share 62.0% in the regional market. The company dominance is a result of the strong brand value of its drugs like Botox & Juvederm. Presently, Botox is leading the market and is expected to retain its stance all throughout 2024.
According to the research report, the North America facial injectables market is expected to reach a valuation of US$5.8 bn by the end of 2024 as compared to US$2.1 bn by the end of 2015. Between the forecast years of 2016 and 2024, the global market is expected to rise at a CAGR of 12.0%.
This 93 page report gives readers a comprehensive overview of the facial injectables market. Browse through 6 data tables and 23 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/north-america-facial-injectables-market.html
U.S. to be Frontrunner in Regional Market with Changing Lifestyles of Consumers
The overall market has been segmented into the U.S. and Canada on the basis of geography. Out of the two countries, the U.S. is expected to assume the lead in the overall market due to a high demand for botulinum toxins and dermal fillers. Improving lifestyles and growing preference for minimally invasive surgeries are expected to drive the demand for facial injectables across the U.S.
In terms of products, the market is segmented into botulinum toxin, hyaluronic acid, collagen, and particle and polymer fillers. Of these, the botulinum toxin segment held a leading share in the global market in 2015 as it is predominantly being used for correcting lines, creases, and wrinkles. Thus, between 2016 and 2024, the botulinum toxin segment is estimated to exhibit a CAGR of 12.7%.
Synthetic Facial Injectables with Long-lasting Effects Propel Demand
Development of synthetic products with polymers and particles has upped the demand for facial injectables across North America. The new products have a longer shelf-life, which prolongs the need to re-treatment. Thus, the widening availability of facial injectables that tend to have permanent effects is driving the demand for products in the overall market. Furthermore, as the frequency of treatment is reduced it has also brought down the cost of facial injectables treatment, thus making it affordable.
The market for facial injectables across North America has also been flourishing against the backdrop of growing preference for minimally invasive surgeries. Thus, the growing inclination toward minimally invasive procedures in dermatological applications is expected to drive the overall market. The growing focus on aesthetics and physical attractiveness are proving to be the persuasive factors in the propelling demand for facial injectables in North America. Changing lifestyles, rising disposable incomes, and altering understanding of beauty and attractiveness is encouraging several users to opt for facial injectables that can reverse the signs of aging to restore the youthful glow.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving facial injectables market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=18515
Side Effects of Facial Injectables Challenge Market Growth
The strength of aforementioned market drivers is likely to be challenged by a few restraints in the North America facial injectables market. The possibility of allergic reactions due to the involvement of living organisms and related chemicals and enzymes is anticipated to hamper the growth of the overall market. Furthermore, side-effects such as edema, bleeding, and bruising are also expected to restrain the growth of the regional market. The poor reimbursement policies associated with facial injectables are expected to curb the spending on these expenditures in the near future.
This review is based on Transparency Market Research’s report, titled “Facial Injectables Market – North America Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”
Ophthalmic Ultrasound Device Market 2024: Trends, Business Strategies and Opportunities with Key Players Analysis
Global Ophthalmic Ultrasound Device Market: Snapshot
The constantly increasing percentage of the geriatric population across the world is widely considered as the primary factor augmenting the demand for ophthalmic ultrasound devices. The high geriatric population is directly linked to the increasing patient count for ocular diseases and disorders, along with chronic diseases such as diabetes. The increasing levels of pollution are also responsible for the high volume of ovular disorders across the world, thereby becoming a key driver for the global ophthalmic ultrasound device market. This market is further being boosted by the need for – and subsequent release of – novel technological developments. However, the global ophthalmic ultrasound device market is also being stifled by factors such as the high costs of acquiring these devices as well as the overall lack of ophthalmologists capable of operating advanced devices.
The global ophthalmic ultrasound device market was valued at US$2.3 bn in 2015. Its revenue is expected to expand at a CAGR of 6.2% within a forecast period from 2016 to 2024 and is estimated to reach US$4.0 bn by the end of 2024.
This 220 page report gives readers a comprehensive overview of the ophthalmic ultrasound device market. Browse through 49 data tables and 70 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/ophthalmic-ultrasound-systems-market.html
A-scan Ophthalmic Ultrasound Devices High in Demand
Based on products, the global ophthalmic ultrasound device market can be segmented into A-scan, B-scan, combined scan, pachymeters, and ultra-bio microscopes (UBM). In terms of value, A-Scan segment emerged as the leading product segment in the global ophthalmic ultrasound device for 2015, accounting for 27.8% of its overall value. A-scan devices are largely used in hospitals, ophthalmic clinics, and research labs to gather results with higher accuracy. The segments of combined scan and B-scan are expected to register an exceptionally fast growth in demand over the given forecast period. Their growth rate is attributed to an increase in the number of cataracts, glaucoma, and other common ocular diseases. UBM devices are projected at an improved growth rate between 2016 and 2024, owing to an increasing rate of technological advances in this segment.
Ophthalmic ultrasound devices are used by end users ranging from ophthalmic clinics, eye research institutes, hospitals, and ambulatory surgical centers. Hospitals dominated the market in 2015 owing to an increasing registration rate of various ocular diseases and the growing scope of device customization offered by several key players. This segment is also expected to grow at a leading rate till 2024.
High Patient Count in North America Puts it at Top of Ophthalmic Ultrasound Device Demand
Geographically, the global ophthalmic ultrasound device market is divided into North America, Europe, Asia Pacific, Latin America, and The Middle East and Africa. North America emerged as the leader in the global ophthalmic ultrasound device market for 2015 with a strong share of 39.8% in its value. This factor is attributed to the rising prevalence of ocular disorders and a significantly higher rate of development of technologies, and better ocular health awareness programs than other regions.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving ophthalmic ultrasound device market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6583
According to the NHS, in the U.K., between 500 and 600 cases of ocular cancer are diagnosed per year, a key concern among the region’s ophthalmologists. This is likely to drive the growth of the European ophthalmic ultrasound devices market. At the same time, Asia Pacific is projected to lead the global ophthalmic ultrasound device market in terms of growth rate over the above forecast period. This prediction is based on the region’s increase in geriatric population, the setup of stronger distribution channels by market leaders, and an improving patient awareness program regarding ocular disease management.
For 2015, the leaders in the global ophthalmic ultrasound device market included Nidek Co. Ltd., Ellex Medical Lasers Ltd., Optos Plc. (Nikon Corporation), Halma Plc., Sonomed, Inc. (Escalon Medical Corp.), Reichert, Inc. (AMETEK, Inc.), and Quantel Medical.
North America Veterinary Radiography Systems Market: Future market projections for forthcoming years
Transparency Market Research has published a new market report titled, “Veterinary Radiography Systems Market: (Product Type: Digital X-ray and Analog X-ray; Technology: Computed Radiography, Digital Radiography, Film Screen Radiography; Application: Orthopedic and Rheumatology, Cardiology, Oncology, Nephrology and Others; End User: Hospitals, Clinics, Diagnostic Centre and Research Centre) – North America Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016–2024”. According to the report, the North America veterinary radiography systems market is projected to reach US$ 294.5 Mn in 2024 at a CAGR of 5.8% from 2016 to 2024.
The rising trend of pet ownership along with rising awareness about animal health, is driving the demand for veterinary radiography systems in North America. Geographically, the market has been segmented into two country markets, i.e. the U.S. and Canada. The U.S. majorly contributed towards the revenue shares of North America veterinary radiography systems market in 2015 due to presence of major market players in the country. Most of the players that are operating in the region have made a series of strategic acquisitions which contributed to the increase in their market share, and also led to the reduction in the competitive environment.
This 117 page report gives readers a comprehensive overview of the North America veterinary radiography systems market. Browse through 11 data tables and 52 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/north-america-veterinary-radiography-systems-market.html
Increasing humanization of pets and adoption of pets in the U.S. drives the animal health care market in the country. Growing trend of using pets as a status symbol is many countries is also expected to fuel the veterinary radiography devices market. Pets are sometimes also adopted for therapeutic and psychological benefits. According to the American Pet Products Association, as of 2016, 70 million to 80 million dogs (approximately 37% to 47% of all households) and 74 million to 96 million cats (30% to 37% of all households) are owned in the U.S. Sports injuries are expected to drive the veterinary radiography devices market. Several sports and adventure events are conducted in the U.S. and is also recording many registrations for the event. In 2010, there were over 940,000 entries in 2,461 American Kennel Club sponsored events. According to the statistics of GREY2K USA (2015), 80,000 greyhounds were registered to race between 2008 and 2014. Since 2008, over 11,700 greyhound injuries have been registered, including more than 3,000 broken legs, several heart attacks, broken necks, and fractured skulls. Increasing accidents during trainings, sports, and adventures is expected to fuel the veterinary radiography devices market.
The increasing U.S. pet industry expenditure will fuel the market of veterinary radiography system market in forecast period. According to the American Pet Products Association statistics, the U.S. pet industry expenditure stood at US$ 58.04 Bn and US$ 60.28 Bn in 2014 and 2015, respectively and is expected to reach US$ 62.75 Bn in 2016. Pets are considered members of a family as they provide companionships to the other members of the family. Hence, residents in the U.S. are ready to spend money for the better quality of their pets. The U.S. government is taking initiatives for the betterment of the health of pets. In 2007, a group of organizations held a summit for the formation of CATalyst council for feline health and welfare. In September 2012, the American Association of Feline Practitioners (AAFP) and the CATalyst Council created program to make practices more cat-friendly. The American Veterinary Medical Foundation (AVMF) created the Veterinary Care Charitable Fund (VCCF) program with effective and simple way to offer better veterinary services to animals release from abuse and neglected as well as to clients facing personal problems.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving North America veterinary radiography systems market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17630
In veterinary radiography systems market the contribution in the market share by Canada was least in 2015 and is further expected to decline during the forecast period owing to many households limiting their veterinarian visits to cut costs. Major players operating in the North America veterinary radiography system market are Sound-Eklin- VCA Company, Idexx Laboratories, Canon, Inc., Fuji Medical Systems, Carestream, Cuattro Veterinary, iM3/Durr Medical, Sedecal and Vetel Diagnostics. These companies offer various systems with several advanced features, hence would lead the North America veterinary radiography system market in the near future as well.
The top seven players in the global drugs of abuse testing market accounted for 63.7% in the market in 2015. The leading players Alere, Inc., F. Hoffmann La-Roche Ltd., Siemens Healthineers (Siemens AG), Thermo Fisher Scientific, Inc., Drägerwerk AG & Co. KGaA, Shimadzu Corporation, and Laboratory Corporation of America Holdings. Of these, Alere Inc. held a dominant share in the global market with its wide product portfolio for drugs of abuse testing, observes Transparency Market Research. “Companies are focused on ensuring organic and inorganic growth through acquisitions and development of new products,” states the lead author of this study.
According to the research report, the global drugs of abuse testing market is estimated to be worth US$6.4 bn by the end of 2024 as compared to US$4.1 bn in 2015. Between the forecast years of 2016 and 2024, the global market is expected to surge at a CAGR of 5.3%.
This 172 page report gives readers a comprehensive overview of the drugs of abuse testing market. Browse through 30 data tables and 83 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/drugs-abuse-testing-market.html
North America Shows Continued Growth in Global Drugs of Abuse Testing Market
In terms of geography, North America is projected to lead the global market as it estimated to rise at a CAGR of 5.7%. The growth of the North America drugs of abuse testing market will be attributable to the ever-growing demand for testing and screening all across the U.S. High level of awareness and efforts to ensure an efficient and safe working place is expected to keep the demand for these screening across the U.S. steady during the forecast period. Out of the various end users, the diagnostic laboratories are projected to lead with a CAGR of 5.3% between 2016 and 2024.
High Prevalence of Drug Abuse Augurs Well for Overall Market
The unfortunate and illicit consumption of drugs across the world has been the primary growth driver for the global drugs of abuse testing market. Rising incidences of substance abuse and its negative impact on the lives of abusers as well as those around them have forced governments and several non-profit organizations to take a stern stand against these harmful activities. Owing to this very reason, several hospitals, offices, diagnostic laboratories, and forensic laboratories are adopting various ways of testing for drug abuse. On-the-spot testing is also gaining traction in order to ensure random checks to reduce the incidence of mishaps due to abuse.
Presence of several clinical laboratories across the globe is yet another reason fueling the demand for drugs of abuse testing products. Growing number of hospitals that depend on laboratories are expected to boost the demand for products such as sample collection devices and analyzers. Furthermore, stringent norms at workplaces to ensure employees are not involved in drugs is expected to augment the demand for work place screening in the coming years. The skyrocketing number of deaths due to rising incidence of abuse of prescription drugs is estimated to drive the market as well.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving drugs of abuse testing market during 2016 – 2024: http://www.transparencymarketresearch.com/drugs-abuse-testing-market.html
Low Rate of Awareness in Developing Economies to Hamper Market
Though the global market has robust growth drivers, it is being tugged in the opposite direction by the lowering reimbursement rates. Poor reimbursement policies are likely to have a negative impact on the growth of the global drugs of abuse testing market. The market is also being restrained by the low rate of awareness in emerging economies of Asia Pacific, Latin America, and Africa. The high poverty and rampant abuse of drugs in these regions is anticipated to act as an impediment for overall market during the forecast period.
This review is based on Transparency Market Research’s research report, titled “Drugs of Abuse Testing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”
Growing Incidence of Congestive Heart Failure Drives Global Dilated Cardiomyopathy Therapeutics Market
Transparency Market Research has published a new report on the global dilated cardiomyopathy therapeutics market. As per the report, the global dilated cardiomyopathy therapeutics market is predicted to decline at a CAGR of -7.0% from 2014 to 2020.The report, titled ‘Dilated Cardiomyopathy Therapeutics Market – Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,’ states that the global market was valued at US$651.0 mn in 2013 and is expected to reach US$328.6 mn by 2020. Factors such as the introduction of gene and stem cell therapies for DCM and the side effects of DCM drugs are expected to restrain the global dilated cardiomyopathy therapeutics market in the years to come.
This 90 page report gives readers a comprehensive overview of the dilated cardiomyopathy therapeutics market. Browse through 5 data tables and 23 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html
Heart failure is primarily caused by dilated cardiomyopathy (DCM). DCM commonly develops in people aged between 20 years and 60 years. DCM is one of the primary factors, which indicates the need of heart transplantation. Approximately 30% to 40% of people genetically inherit DCM. Factors such as thyroid disorders, diabetes, a viral infection in the heart valve, and alcoholism could cause DCM. As per the Pediatric Cardiomyopathy Registry, dilated cardiomyopathy affects 6 out of 1 million children. DCM is commonly diagnosed in young children, the common diagnosis age being 2 years.
The global dilated cardiomyopathy therapeutics market is segmented on the basis of region and drug class. Some of the commonly used drug classes in DCM treatment are aldosterone antagonists, angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, and beta blockers. In 2013, the angiotensin II receptor blockers (ARBs) segment held the largest share in the global dilated cardiomyopathy therapeutics market. In 2013, the beta blockers segment was the second largest segment in the global dilated cardiomyopathy therapeutics market.
The increasing incidence of congestive heart failure is expected to drive the global dilated cardiomyopathy therapeutics market in the coming few years. DCM accounts for 30% to 40% of congestive heart failure cases every year, reports suggest. Considering the increasing incidence of congestive heart failure, leading players have started initiating many clinical trial studies for DCM. Going forward, a global rise in the number of heart failure cases is expected to increase the demand for effective treatments. This is expected to drive the global dilated cardiomyopathy therapeutics market in the near future. The global market is expected to be hampered by the rising availability of implantable devices and the side effects of DCM drugs.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving dilated cardiomyopathy therapeutics market during 2014 – 2020: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2293
Based on geography, the global dilated cardiomyopathy therapeutics market is divided into Asia Pacific, Europe, North America, and Rest of the World. In 2013, in terms of revenue, North America held a massive share in the global dilated cardiomyopathy therapeutics market due to the increasing acceptance of branded drugs and the increasing incidences of congestive heart failure here.
Some of the key companies operating in the global dilated cardiomyopathy therapeutics market are Array BioPharma, Inc., Celladon Corporation, Janssen Pharmaceuticals, Inc., Novartis International AG, Sanofi S.A., Vericel Corporation, and AstraZeneca plc.